- Ongoing Phase II trial which compared efficacy of pembrolizumab and its combination with chemotherapy- It also recruited NSCLC patients bearing EGFR T790M who have acquired resistance to osimertinib. Here, EGFR is linked to non-small cell lung carcinoma.